Drug Trial Radar · NCT05384119
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Jan 9, 2023
Primary completion
May 6, 2024
Study completion May 6, 2024
Sponsor
- Lead sponsor
- Tvardi Therapeutics, IncorporatedIndustry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal receptor 2-negative (HER2)- palbociclib-resistant breast cancer, and to determine the recommended Phase 2 dose (RP2D) for TTI-101 when added to palbociclib and AI or fulvestrant. The primary objective of Phase 2 will be to evaluate anti-tumor activity in participants who receive TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
Conditions
- Breast Cancer
Interventions
TTI-101Drug
Oral tablet
PalbociclibDrug
Oral capsule
Aromatase inhibitor (AI)Drug
Oral tablet
fulvestrantDrug
Oral tablet
ribociclibDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Day 1 to Day 28
- Phase 1b: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 17 months
- Phase 1b: Number of Participants Who Experience a Serious Adverse Event (SAE)Time frame: Up to approximately 17 months
- Phase 2: Landmark Progression Free Survival at 6 Months (PFS6)Time frame: 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Holy Cross Health Fort Lauderdale - Holy Cross Hospital
Fort Lauderdale, Florida
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee
Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.